Advertisement
GNPX vs ICU
Which Stock Would AI Choose? Genprex (GNPX) vs. SeaStar Medical (ICU) Stock Comparison
Key Takeaways
- GNPX (Genprex) is a pre-revenue, clinical-stage gene therapy developer, while ICU (SeaStar Medical) is a commercial-stage medical device company generating growing revenue.
- Relative performance favors ICU, which has observable commercial traction, expanding hospital adoption, and analyst coverage; GNPX has relied heavily on financing and repeated share consolidations.
- Tickeron AI Verdict: ICU (SeaStar Medical) currently presents the more consistent trend profile and clearer near-term catalysts of the two.
- Both names carry elevated risk as loss-making micro-caps, but their risk profiles differ materially in business maturity and cash needs.
- For more detail, explore GNPX Major News and GNPX Today's Price Move, as well as ICU Major News and ICU Today's Price Move.
- To see how AI-driven strategies are navigating the current market, visit Trending AI Robots.
Introduction
Investors screening speculative healthcare names frequently encounter Genprex (GNPX) and SeaStar Medical (ICU) side by side. Both are Nasdaq-listed, loss-making micro-caps with small floats, active retail followings, and binary catalysts tied to clinical and regulatory milestones. Yet their business models sit at opposite ends of the development spectrum. This stock comparison is most relevant to traders and investors weighing relative performance, market positioning, and risk tolerance between a pre-revenue biotech and a revenue-generating medical device firm operating in critical care.
GNPX Overview and Recent Performance
GNPX, or Genprex, is a clinical-stage gene therapy company focused on oncology and diabetes. Its lead candidate, REQORSA (quaratusugene ozeplasmid), is being studied in lung cancer, while GPX-002 targets diabetes. Recent weeks have brought a steady flow of news: a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer (NSCLC), patent grants across Japan, Europe, Israel, Australia, and Canada, and additional preclinical data presented at major oncology and gene therapy conferences. These developments have periodically sparked sharp intraday moves.
Despite the headline activity, GNPX's relative performance has been weak over the broader period. The company generates no product revenue, has used multiple reverse stock splits to maintain its listing, and relies on ongoing share issuance to fund operations, resulting in notable dilution. Insider selling and a shrinking share price have compounded a downtrend, leaving market capitalization in the low single-digit millions. Sentiment remains event-driven, with sharp rallies on individual announcements rather than sustained accumulation.
ICU Overview and Recent Performance
ICU, or SeaStar Medical Holding Corporation, is a commercial-stage healthcare company developing the Selective Cytopheretic Device (SCD), a platform that modulates the immune overreaction (hyperinflammation) that can damage organs in critically ill patients. Its commercial product, QUELIMMUNE (SCD-PED), treats pediatric acute kidney injury (AKI) associated with sepsis, while the NEUTRALIZE-AKI pivotal trial is evaluating the adult AKI opportunity.
In recent quarters, ICU has shown tangible commercial progress. Revenue has grown substantially year over year, and the company has expanded its base of pediatric hospital customers while reaffirming a full-year revenue target. The U.S. Food and Drug Administration (FDA) confirmed that QUELIMMUNE's post-approval SAVE Registry fulfilled its requirements, a positive regulatory milestone. However, the stock has declined in recent weeks amid concerns about a thinning cash balance, slower-than-targeted pivotal trial enrollment, and a secondary share distribution. Analyst coverage remains constructive, with a Buy rating and price target well above recent trading levels.
Trending AI Robots
Tickeron operates a large ecosystem of AI-powered trading bots spanning thousands of tickers, each built with its own trading style, strategy, timeframe, and performance profile. Because market conditions shift, only a subset of these bots is well suited to the current environment at any given moment. That is the purpose of the Trending AI Robots page: a curated selection of the top-performing and most relevant strategies, rather than the full catalog. The bots vary widely in how they identify setups, manage risk, and rotate across positions, so the curated list serves as a practical starting point for traders comparing systematic approaches. Exploring the Trending AI Robots section can help you see how algorithmic strategies are positioning across names like these.
Head-to-Head Comparison
The core contrast between these two stocks is stage of development. GNPX is pre-revenue, meaning its value hinges almost entirely on clinical data, intellectual property, and the ability to raise capital. ICU, by contrast, already sells a regulated medical device and is converting clinical momentum into recurring hospital accounts. This gives ICU a measurable revenue stream and a clearer operational benchmark, whereas GNPX trades on forward-looking scientific milestones.
Growth drivers also differ. GNPX's catalysts are largely preclinical or early-stage clinical readouts and patent expansion, which are high-impact but uncertain. ICU's drivers are commercial adoption, customer count growth, and pivotal trial enrollment, which are slower-moving but more observable. Risk factors diverge accordingly: GNPX faces heavy dilution and repeated share consolidation, while ICU faces cash runway constraints and financing overhang. Sector exposure overlaps in healthcare, but GNPX sits in gene therapy oncology, and ICU in critical-care medical devices. Market sentiment has favored ICU's relative positioning on the strength of real-world commercial validation, even as both stocks remain volatile.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would currently lean toward ICU (SeaStar Medical) over GNPX (Genprex). The rationale is rooted in ICU's revenue generation, expanding hospital customer base, analyst coverage, and a more clearly defined path toward regulatory and commercial milestones. GNPX, while rich in scientific news flow, remains pre-revenue with a history of financing-driven dilution and consolidation that has pressured its trend profile. This assessment is probabilistic rather than definitive, and both micro-cap names warrant careful risk consideration under any scenario.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNPX is a Hold and ICU is a Hold.
GNPX saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for GNPX moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 32 similar instances where the indicator exited the overbought zone. In 32 of the 32 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GNPX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GNPX's RSI Oscillator exited the oversold zone, 36 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on GNPX as a result. In 60 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +11.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in 150 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
GNPX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.115) is normal, around the industry mean (3.498). P/E Ratio (0.060) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. GNPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ICU in downward trend: 10-day moving average crossed below 50-day moving average on October 21, 2026
The 10-day moving average for ICU crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ICU as a result. In 80 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ICU turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 34 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
ICU moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ICU moved below the 200-day moving average on October 20, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ICU entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for ICU's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICU advanced for three days, in 150 of 183 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ICU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.929) is normal, around the industry mean (3.498). P/E Ratio (-0.995) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.468) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. ICU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
GNPX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 93 | |
P/E GROWTH RATING 1..100 | 84 | |
SEASONALITY SCORE 1..100 | 29 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| GNPX | ICU | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 87% |
| MACD ODDS (%) | N/A | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| Advances ODDS (%) | 13 days ago 76% | 16 days ago 82% |
| Declines ODDS (%) | 3 days ago 90% | 6 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 87% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GNPX’s FA Score shows that 0 FA rating(s) are green while ICU’s FA Score has 1 green FA rating(s).
- GNPX’s FA Score: 0 green, 5 red.
- ICU’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GNPX’s TA Score shows that 4 TA indicator(s) are bullish while ICU’s TA Score has 4 bullish TA indicator(s).
- GNPX’s TA Score: 4 bullish, 3 bearish.
- ICU’s TA Score: 4 bullish, 7 bearish.
Price Growth
GNPX (@Biotechnology) experienced а -9.52% price change this week, while ICU (@Biotechnology) price change was -5.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
GNPX is expected to report earnings on Nov 13, 2026.
ICU is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
GNPX and
Correlation & Price change
A.I.dvisor indicates that over the last year, GNPX has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if GNPX jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To GNPX | 1D Price Change % | ||
|---|---|---|---|---|
| GNPX | 100% | +1.46% | ||
| CANF - GNPX | 93% Closely correlated | -1.19% | ||
| APVO - GNPX | 86% Closely correlated | -4.42% | ||
| ICU - GNPX | 82% Closely correlated | -3.06% | ||
| MLEC - GNPX | 76% Closely correlated | N/A | ||
| LONA - GNPX | 76% Closely correlated | -10.07% | ||
More | ||||
ICU and
Correlation & Price change
A.I.dvisor indicates that over the last year, ICU has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if ICU jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To ICU | 1D Price Change % | ||
|---|---|---|---|---|
| ICU | 100% | -3.06% | ||
| CANF - ICU | 93% Closely correlated | -1.19% | ||
| APVO - ICU | 85% Closely correlated | -4.42% | ||
| GNPX - ICU | 82% Closely correlated | +1.46% | ||
| TNXP - ICU | 77% Closely correlated | -8.69% | ||
| LONA - ICU | 62% Loosely correlated | -10.07% | ||
More | ||||